Economic Burden Associated With Nintedanib Non-adherence Among Medicare Beneficiaries With IPF

Study identification

• EU PAS number:
  EUPAS1000001177
• Study ID:
  1000001177
• Official title and acronym:
  Economic Burden Associated With Nintedanib Non-adherence Among Medicare Beneficiaries With IPF
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  This study has two objectives:; -To assess the association between nintedanib adherence trajectory group (as measured from a Group-based Trajectory Modelling (GBTM)) and health care resource use, with a focus on inpatient hospitalization, among patients with Idiopathic Pulmonary Fibrosis (IPF).; -To assess the association between a patient's nintedanib adherence trajectory group (as measured from a GBTM) and their medical costs among patients with IPF.
• Study status:
  Finalised

Research institutions and networks

Institutions

Boehringer Ingelheim

Study timelines

Date when funding contract was signed

Actual:16/05/2023

Study start date

Actual:16/05/2023

Date of final study report

Actual:30/06/2023

Sources of funding

More details on funding

No information provided.

Regulatory

• Was the study required by a regulatory body?:
  Unknown
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

1199-0520; NCT05870956